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Aim. To study whether use of neoadjuvant androgen deprivation therapy (N-ADT) combined with whole pelvic radiotherapy
(WPRT) for high-risk prostate cancer patients was associated with survival beneﬁt over prostate radiotherapy (PORT) only.
Material and Methods. Between 1999 and 2004, 162 high-risk prostate cancer patients were treated with radiotherapy combined
with long-term androgen deprivation therapy (L-ADT).Patients were prospectively assigned into two groups: A (N-ADT + WPRT
+ L-ADT) n = 7 0p t s ,B( P O R T+L - A D T )n = 92pts. Results. The 5-year actuarial overall survival (OS) rates were 89% for A and
78% for B (P = .13). The 5-year actuarial cause speciﬁc survival (CSS) rates were A = 90% and B = 79% (P = .01). Biochemical
progression-free survival (bPFS) rates were 52% versus 40% (P = .07), for groups A and B, respectively. Conclusions.T h eW P R T
combined with N-ADT compared to PORT for high-risk patients resulted in improvement in CSS and bPFS; however no OS
beneﬁt was observed.
Copyright © 2009 Piotr Milecki et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The number of diagnosed new cases of prostate cancer is
increasing in the United States as well in the European Union
[1–3]. Additionally, for the last decades signiﬁcant migration
of clinical stages has been observed which resulted in rise
in the number of patients in low or intermediate risk of
relapse [4]. On the other hand, the number of patients
representing an advanced stage of disease, which is related to
the high-risk of relapse, is decreasing. Despite these facts, a
signiﬁcant number of patients constitute the high-risk group
with high probability of micrometastases in the regional
lymph nodes. For this group optimal management remains
controversial. The role of radiotherapy (RT) in treatment of
high-risk prostate cancer is generally established, although
there are still many controversies concerning the optimal
total dose, deﬁnition of irradiated volume (whole pelvis
versus prostate only), and ways of the most eﬃcient com-
bination with androgen deprivation therapy (neoadjuvant
versus adjuvant and the timing of androgen deprivation)
[5]. Several clinical studies have demonstrated that RT
combined with adjuvant long-term androgen deprivation
therapy (L-ADT) for high-risk patients is associated with
improved biochemical progression-free survival (bPFS),
cause-speciﬁc survival (CSS), and overall survival (OS) [6–
9]. However, these studies did not compare the whole pelvic
radiotherapy(WPRT)combinedwithneoadjuvantandrogen
deprivation therapy (N-ADT) and L-ADT with prostate
radiotherapy only (PORT) combined with L-ADT [10, 11].
In consequence, the eﬀectiveness of the regional lymphatic
network irradiation combined with N-ADT has not been
established. It is extremely important to evaluate the role of
WPRT because pelvic irradiation could raise the intensity
of side eﬀects [12, 13]. Thus, the question arises about the2 Journal of Biomedicine and Biotechnology
therapeutic gain related to WPRT combined with N-ADT
over the prostate only irradiation [14–17].
2. Purpose
The aim of this study was to evaluate whether N-ADT
combined with WPRT and L-ADT is associated with survival
beneﬁt over PORT and L-ADT for the cohort of patients
deﬁned as the high-risk group of prostate cancer.
3.MaterialsandMethods
3.1. Patient Characteristics. From May 1999 to December
2004, 162 patients were entered into prospective comparison
study. All patients deﬁned as the high risk were treated with
three-dimensional conformal radiotherapy (3D CRT) and
L-ADT at the Greater Poland Cancer Center in Poznan,
Poland. All patients represented good general performance
status deﬁned as 0 or 1 according to the Eastern Cooperative
Oncology Group (ECOG) classiﬁcation. All patients had a
histological diagnosis of adenocarcinoma classiﬁed accord-
ing to Gleason score. Patients were classiﬁed as the high-risk
patients when at least one of the following conditions was
present: Gleason score >7 or initial prostate-speciﬁc antigen
(PSA) level >20ng/mL or T3. Patient’s characteristics are
presented in Table 1.
Statistic analysis was conducted to explore the balance of
knownprognosticfactorsinthetwogroups.Thedistribution
of age, Gleason score, PSA, and risk of lymph nodes
metastases was similar between the two groups (Table 1).
The average level of PSA before the beginning of
treatment was for the group A 37.3ng/mL (range: 19–
70ng/mL) and for the group B 38.1ng/mL (range: 6–
70ng/mL). All patients before starting treatment had bone
scan and chest X-ray. Pelvic lymph nodes were evaluated
by computer tomography. Only patients with no signs of
metastases in these examinations were treated with radical
intent. We did not perform diagnostic lymphadenectomy of
the pelvic lymph nodes. The median level of risk metastases
to lymph nodes based on the formula proposed by Roach
III et al. for all patients was 32% (range: 23%–67%) [18].
Treatment strategy (N-ADT + WPRT versus PORT) for
individual patient was chosen after discussing all cons and
pros of two methods with treating physicians (urologist and
radiation oncologist). As many as 70 out of 162 (43%)
patients chose WPRT with N-ADT (group A). The second
option of treatment (PORT + L-ADT) was chosen by 92
(57%) of 162 patients (group B).
3.2. Androgen Deprivation Therapy (ADT). All patients
included into group A have started N-ADT immediately
after conﬁrmation of histological diagnosis. All patients
were treated with LHRH analogs started on a 1 monthly
preparation of gosereline acetate and then moved to 3-
monthly 10.8mg depot preparation. Additionally, patients
received two weeks before LHRH analog treatment a short-
time antiandrogen therapy to prevent the ﬂare syndrome
(ﬂutamide 250mg p.o. tid for 4 weeks). N-ADT duration
rangedfrom2to10months(median4.4months).Androgen
deprivation therapy was also continued during the course of
RT. All patients (group A and group B) were treated with
L-ADT (LHRH analog) from the last day of irradiation.
The median duration of L-ADT was 28.4 months (range:
3–37) and 29.1 months (range: 9–39) for the group A and
group B, respectively. In case of biochemical failure (the PSA
recurrence deﬁned according to the Phoenix deﬁnition) [19]
an antiandrogen was added to LHRH analog as a second
line hormonal therapy or the LHRH analog was introduced
again.
3.3. Radiotherapy Technique. Simulation and treatment were
performed in a supine position (using knee support and
laser beams) with “comfortable” full bladder ﬁlling. For
radiotherapy planning all patients underwent pelvic CT scan
in the treatment position; 5-mm slice thickness is used from
the top of iliac bone to at least 5cm below the base of the
penis. For all patients the following organs at risk (OAR)
were outlined: bladder, rectum, intestine, and femoral heads.
Planning target volume 2 (PTV 2) was the pelvic lymph
nodes (the obturator, hypogastric, presacral, internal, and
external iliac nodes) and prostate with seminal vesicles with
a 1cm margin and was treated with total dose of 46Gy.
Therefore, the superior border of the ﬁeld was placed at the
levelofdivisionofcommoniliacvessels.PTV1encompassed
the prostate and seminal vesicles with 1cm margin, except
posterior part of PTV 1 where 0.5cm margin was added.
The reproducibility of the irradiated ﬁelds was checked
by electronic portal imaging device (EPID) performed at
the start of the treatment (the ﬁrst day of irradiation) and
weakly thereafter or when the treatment phase was changed.
In vivo dosimetry based on termoluminescence dosimetry
(TLD) was performed for each patient at the beginning
(usually at the ﬁrst day of irradiation) and in the middle of
the treatment. Radiotherapy was administered using 20MV
photon beam (Clinac 2300 CD, Varian) in a daily fraction
of 1.8Gy or 2.0Gy for the total median dose of 70.2Gy
(range: 66Gy–74Gy). In each case 3D CRT was based on
3-ﬁeld or 4-ﬁeld techniques with the application of the
multileaf collimators [20]. For the subgroup of patients
irradiated to pelvic the total median dose was46.4Gy (range:
44Gy–50Gy) which was applied with box technique (4-ﬁeld
technique).
Acute side eﬀects were evaluated during the irradia-
tion course and than 1 month after the completion of
treatment using the Radiation Therapy Oncology Group
(RTOG)/the European Organization on Radiation Therapy
Criteria (EORTC) morbidity scoring scale [21]. Late side
eﬀects were evaluated according to the RTOG/EORTC scale
during each visit.
3.4. Followup. Patients were seen one month after the
completion of radiotherapy and every 3 months thereafter.
Patients alternated their appointments between their urolo-
gists and radiation oncologists. During each visit serum PSA
level was determined and additionally digital rectal exami-
nation (DRE) and clinical evaluation were performed. The
Tandem-R monoclonal method with detection sensitivity of
0.02ng/mL was used for PSA measurement. The medianJournal of Biomedicine and Biotechnology 3
Table 1: Patient’s characteristics entered into prospective study for high-risk patients (n = 162).
C h a r a c t e r i s t i c W P R T+N - A D T( g r o u pA ) P O R T( g r o u pB ) P∗
Patients (n) 70 (100%) 92 (100%) —
Mean age (years) 68.1 (range: 47–78) 67.9 (range: 48–79) .81
Gleason score
2–7 34 (49%) 50 (55%) .56
8–10 36 (51%) 42 (45%)
Clinical stage
T2c 20 (29%) 44 (48%) .005
T3 50 (71%) 48 (52%)
Total dose 70.1Gy 70.3Gy .22
PSA (ng/mL)
<30 25 (36%) 41 (44%) .32
>30 45 (64%) 51 (56%)
%N+
<30% 19 (27%) 38 (41%) .088
>30% 51 (73%) 54 (59%)
Duration of L-ADT (months) 28.4 29.1 .13
Median followup (months) 54 55 .21
WPRT: whole pelvic radiotherapy, PORT: prostate radiotherapy only, PSA: prostate speciﬁc antigen, N-ADT: neoadjuvant androgen deprivation therapy, L-
ADT: long-term adjuvant androgen deprivation therapy, %N+: probability of metastases to pelvic lymph nodes calculated according to the Roach formula
[18].
∗Unpaired t-test for continuous variables; chi-square test for categorical variables.
followup duration was 54 months (range: 6–101 months)
and 55 months (range: 7–99 months) for groups A and B,
respectively.
3.5. Statistics. Primary endpoints for analysis were over-
all survival (OS), cause speciﬁc survival (CSS), dis-
tant metastases-free survival (DMFS), and biochemical
progression-freesurvival(bPFS).OSreﬂectedalldeaths,CSS
reporteddeathsthatcouldbeattributedtoprostatecancer.In
those cases for which the cause of death was unclear, death
was considered as a result of prostate cancer in case when
clinically evident prostate cancer was present at the time of
death.
The biochemical progression endpoint (PSA) for which
outcome was compared was based on the recommendations
of the RTOG-ASTRO Phoenix consensus [19]. This deﬁni-
tionwasselectedbecauseitismoreaccuratethanwidelyused
ASTRO deﬁnition [22], especially for patients treated with
RT and ADT.
Actuarial results for OS, CSS, DMFS, bPFS, and for
late morbidities rates were calculated using the Kaplan-
Meier method. The log rank test was performed to ﬁnd the
correlations between the actuarial results of treatment for
the following clinical parameters: age, T stage, Gleason score,
PSA, WPRT + N-ADT, PORT. For these calculations P-value
of ≤.05 was considered as statistically signiﬁcant.
4. Results
The 5-year actuarial OS rates were 89% and 78% for group
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Figure 1: The Kaplan-Meier curves comparing overall survival
(OS) for patients at high risk of nodal involvement, as deﬁned in
text receiving whole pelvic radiotherapy (WPRT) combined with
neoadjuvant androgen deprivation therapy (N-ADT) or prostate
radiotherapy only (PORT), (P = .13).
(log rank test, P = .13) (Figure 1). The 5-year actuarial CSS
rates were 90% and 79% for the groups A and B, respectively
(long rank test, P = .01) (Figure 2). The 5-year bPFS
rates were 52% versus 40% (P = .07), for groups A and
B, respectively (Figure 3). Distant metastases-free survival
(DMFS) for patients at high-risk of nodal involvement,
as deﬁned in text, was statistically signiﬁcantly better for
































0 1 02 03 04 05 06 07 0




Figure 2: The Kaplan-Meier curves comparing cause speciﬁc
survival (CSS) for patients at high-risk of nodal involvement,
as deﬁned in text receiving whole pelvic radiotherapy (WPRT)
combined with neoadjuvant androgen deprivation therapy (N-
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Figure 3: The Kaplan-Meier curves comparing biochemical
progression-free survival (bPFS) for patients at high-risk of nodal
involvement, as deﬁned in text receiving whole pelvic radiotherapy
(WPRT) combined with neoadjuvant androgen deprivation ther-
a p y( N - A D T )o rp r o s t a t er a d i o t h e r a p yo n l y( P O R T ) ,( P = .07).
On multivariate analysis combined treatment (WPRT +
N-ADT) (P = .01), lower PSA level (P = .01) and lower
risk of lymph nodes involvement (P = .01) were statistically
signiﬁcantly associated with longer CSS (Table 3).
4.1. Acute and Late Side Eﬀects. Generally, RT in both groups
w a sw e l lt o l e r a t e d( Table 2). These symptoms typically
appeared during the third week of treatment and resolved
within a few weeks later. Late side eﬀects grade 2 were noted
in minority of patients. No grade 4 toxicities were noted for
gastrointestinal and genitourinary tracts.
5. Discussion
Our study showed that short N-ADT combined with
WPRT and L-ADT provides signiﬁcant advantage to PORT
combined with L-ADT in terms of CSS, DMFS, and
bPFS. There was no OS beneﬁt for the WPRT combined
with N-ADT in comparison to PORT. Obviously, longer
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Figure 4: The Kaplan-Meier curves comparing distant metastases-
freesurvival(DMFS)forpatientsathigh-riskofnodalinvolvement,
as deﬁned in text receiving whole pelvic radiotherapy (WPRT)
combined with neoadjuvant androgen deprivation therapy (N-
ADT) or prostate radiotherapy only (PORT), (P = .04).
and bPFS to OS. Interestingly, one of the last reviews
conducted by Dirix et al. indicated similar conclusions
from other studies [23]. At present, conformal radiotherapy
is one of the most popular modality of treatment for
patients with intermediate and high-risk groups of prostate
cancer. According to the American Urology Association
(AUA), National Cancer Comprehensive Network (NCCN),
National Cancer Institute (NCI), and the European Urology
Association (EUA) guidelines the 3D CRT combined with
ADT is the most advocated standard of care for patients with
high-risk of relapse [24–26]. These guidelines are based on
several randomized clinical trials which have demonstrated
the beneﬁt of combined therapy (radiotherapy plus ADT)
[27, 28]. However, the optimal timing and duration of
hormonal treatment which is combined with radiotherapy
remains unresolved [29].
The main limitation of our study is that its nonrandom-
ized trial and thus, it can introduce selection bias. Moreover,
while the comparison of study groups (Table 1) showed
that they were similar, group A (N-ADT plus WPRT) had
marginally more aggressive tumors (more patients with GS
8–10 or T3 tumors, higher PSA, and higher risk of lymph
node metastases). Thus, one might generate the hypothesis
that the small beneﬁt of WPRT combined with N-ADT
would be grater (and diﬀerence in OS could be signiﬁcant)
if the study groups were better balanced. Deﬁnitely, well
designed controlled studies are warranted to check such
hypothesis. For example, Wang and Lawton stated that
further studies of above mentioned issues are necessary to
deﬁne the best treatment for patients with high risk of pelvic
l y m p hn o d ei n v o l v e m e n t[ 30].
In our study, heterogeneity of therapy modalities used
in group A (N-ADT plus WPRT) can blur the ﬁnal ﬁndings
of our analysis. Thus, it is impossible to indicate exactly the
factor or factors (WPRT only or N-ADT only or WPRT + N-
ADT) which were responsible for the achieving better results
thanthoseingroupB.Ontheotherhand,clinicaltrialRTOG
94-13 suggested that beneﬁt of WPRT could be achieved if
large volume was connected with N-ADT.Journal of Biomedicine and Biotechnology 5
Table 2: Acute and late gastrointestinal and genitourinary side eﬀects reported in study for high-risk patients (n = 162).
Side eﬀects WPRT + N-ADT (group A) n = 70 PORT (group B) n = 92 P∗
Genitourinary acute
Grade 1 42 (60%) 50 (55%)
.56 Grade 2 17 (25%) 18 (21%)
Grade 3 2 (3%) 3 (3%)
Gastrointestinal acute
Grade 1 50 (71%) 48 (52%)
.32 Grade 2 25 (36%) 41 (44%)
Grade 3 45 (64%) 51 (56%)
Genitourinary late
Grade 1 19 (27%) 38 (41%)
.088 Grade 2 51 (73%) 54 (59%)
Grade 3 3 (%) 3 (%)
Gastrointestinal late
Grade 1 51 (71%) 69 (52%)
.32 Grade 2 5 (36%) 5 (44%)
Grade 3 2 (%) 3 (%)
WPRT: whole pelvic radiotherapy, PORT: prostate radiotherapy only.
Table 3: Univariate and multivariate analysis of clinical and treatment factors predicting for cause speciﬁc survival (n = 162).
Factor P Hazard ratio (95% conﬁdence interval)
Univariate∗ Multivariate
WPRT + N-ADT versus PORT .01 .03 2.4 (1.5–3.1)
Age (<70 versus >70) .23 — —
PSA level (<30 versus >30) .09 — —
T stage (T2c versus T3) .1 — —
Gleason score (2–7 versus 8–10) .02 .04 1.3 (1.08–2.5)
%N+( <30 versus >30) .001 .03 2.1 (1.4–2.2)
WPRT: whole pelvic radiotherapy, N-ADT: neoadjuvant androgen deprivation therapy, PORT: prostate radiotherapy only, PSA: prostatic speciﬁc antigen,
%N+: probability of metastases to pelvic lymph nodes calculated according to the Roach formula [18].
∗Kaplan-Meier analysis log-rank P-value.
Androgen deprivation therapy could be combined with
RT in many ways, for example, as only N-ADT, or on the
other hand, as only L-ADT, or combination of both. In
addition, apart from diﬀerent possibilities of adding ADT
and duration of therapy, the diﬀerences in irradiated clinical
target volume (PORT only or WPRT) may inﬂuence the
results of therapy. One of the studies which indicated a
survival beneﬁt of N-ADT combined with WPRT was RTOG
86-10 trial [31]. In this study, the beneﬁts were limited to a
group of patients with bulky disease and Gleason scores of 2
to 6. Reanalysis of conducted RTOG trials indicated that N-
ADT could be beneﬁcial only in a group of patients extended
to T1, T2, and Gleason score of 7. However, there is no
clear statement concerning the implementation of N-ADT
when radiotherapy is fundamental method of treatment for
patients with high risk of relapse. WPRT alone (without
ADT) has a weak inﬂuence on the results of treatment
[12, 14]. Probably dose in range from 44Gy to 50Gy is
too low to eﬃciently “sterilize” lymph nodes from cancer
cells. In addition, another factor which is responsible for
disappointing results of WPRT without N-ADT is high
risk of distant metastases when high risk involvement of
lymph nodes is noted. It is obvious that for these patients
even eﬃcient loco-regional therapy has small impact on
distant metastases and in consequence on overall survival.
Thus, many investigators in clinical trials are looking for
eﬃcient systemic therapy for this group of patients [32]. The
simplest and most convenient way of realizing such scenario
in clinical practice would be implementation of ADT. For
example, the importance of N-ADT combined with RT was
investigated by D’Amico et al. in randomized trial where 6-
month N-ADT was compared with radiotherapy alone [33].
Patients included into this study were classiﬁed as a high-risk
group. What is worth adding, no pelvic irradiation (WPRT)
had been performed. In conclusion, after the median 45-
months followup, authors stated that signiﬁcant OS beneﬁt
was noted when 6 months of N-ADT were implemented.
Another important issue is the duration of N-ADT when it is
combined with radiotherapy. Trial performed by D’Amico et
al. indicated that 6 month N-ADT is beneﬁcial. Is there any
diﬀerence in eﬀectiveness when short N-ADT (3 months)
is combined with radiotherapy? The Canadian trial which6 Journal of Biomedicine and Biotechnology
compares short-term N-ADT (3 months) with long-term
N-ADT (8 months) [34] showed that longer ADT has no
advantageovershorttherapyin thehigh-risk patients. Inour
study the median time of N-ADT was 4.4 months and was
similar to proposed in majority of clinical trials. Similarly,
beneﬁtofshort-termADT,inparticularinhigh-riskpatients,
was demonstrated in the EORTC study conducted by Bolla
et al., Denham et al., and in the Australian study [35, 36].
Another very important issue is evaluation of the role
of L-ADT when N-ADT is combined with radiotherapy.
In literature there are many well prepared clinical studies
which proved that long-term adjuvant ADT is more eﬃcient
than PORT alone. One of the examples is study conducted
by RTOG (RTOG 9202) where N-ADT was introduced 2
months prior to irradiation (short term of N-ADT) and then
wascontinuedduringradiotherapy[6].Intheinvestigational
arm the patients were treated with ADT for 2 years after the
end of radiotherapy. In a group of patients treated with L-
ADT and radiotherapy the 5-year OS rate was 80%, while in
the group of patients treated without additional hormonal
therapy was 69%, respectively. Another well documented
study, which showed a therapeutic beneﬁt, had been carried
out by Bolla et al. who conﬁrmed that L-ADT conducted for
3yearsresultedinanincreaseof5yearsOSfrom62%to79%
(P = .001) [27]. However, ADT combined with radiotherapy
in high-risk group of patients gives poor results.
In our study L-ADT (28 months) was added in both
treatment groups. ADT duration was similar to reported




arm with PORT combined with the L-ADT. As a result, these
trials could not test the role of WPRT combined with N-
ADT and L-ADT when in comparison arm was not included
PORT with L-ADT. RTOG 9202 study indicated that L-ADT
is better strategy of treatment for high-risk patients than
short-term N-ADT. However, this study did not evaluate the
role of WPRT on the results of treatment.
One of the crucial clinical trials which aim is to answer
the question concerning the role of WPRT combined with
N-ADT is RTOG 9413 [10, 11, 15]. This is a four-arm trial
which is trying to evaluate the role of WPRT combined
with short N-ADT or short adjuvant ADT (4 months). The
early results indicated that implementation of WPRT and
short N-ADT had no advantage over PORT plus N-ADT
and short-adjuvant ADT or PORT plus short-adjuvant ADT.
After followup of 44 months there was no beneﬁt in OS, but
the results deﬁned as CSS, DMFS, bPFS were signiﬁcantly
better for WPRT combined with N-ADT. Comparison of
all four arms indicated that a clear beneﬁt for patients
treated with WPRT and N-ADT (4-year disease-free survival
of 60%) was over all three other arms (44% versus 49%
versus 50%, resp.; P = .008). RTOG 9413 study speciﬁcally
addressed the issue of treatment volume and demonstrated
a sequence dependent beneﬁt associated with WPRT and N-
ADT. This trial demonstrated that when N-ADT is applied
in conjunction with irradiation (WPRT) it yields a better
progression disease-free survival than PORT even for low
dose of irradiation (46Gy) to the pelvis. Comparison of
this trial with our study indicated the diﬀerences in the
applied L-ADT. In our study, the L-ADT (28 months) had
been implemented for both arms (PORT and WPRT). Our
study in this aspect was similar to RTOG 9202 and EORTC
22863. This is clear and very important statement, because
in the trial RTOG 9413 only short (4 months) adjuvant
ADT was implemented. Results of RTOG 9413 and our
study suggested that the addition of ADT before starting
of irradiation could be regarded as the additional biological
dose,whichkillssomenumberofclonogeniccancercellsand
creates better treatment conditions for further radiotherapy.
Of course, the decreasing level of PSA after N-ADT cannot
be interpreted as proportional diminishing of the number
of cancer cells. It should be underlined that the latest
update of trial 8610 stated in conclusion that the addition
of 4 months of N-ADT to radiotherapy has a dramatic
impact on clinically meaningful end points in men with
locally advanced disease [37]. The most important clinical
trials in which hormonal therapy has been combined with
radiotherapy were implementing WPRT.
One of the most important issues of our study is the
early and late toxicities. Our results indicated that the
level of toxicities was acceptable. Although, according to
our observations in the group treated with the N-ADT
and WPRT the intensity of early and late toxicities was
more pronounced. However, N-ADT caused the signiﬁcant
reduction in the volume of irradiated organs at risk because
of reduced volume either of prostate cancer or volume of
the enlarged prostate gland. The median reduction of target
volume observed by Zelefsky et al. was 25% [38]. On the
other hand, in the ﬁrst phase of irradiation (WPRT) more
healthy tissue was irradiated. When aiming to minimize
the side eﬀects it is important to introduce the N-ADT
2–3 months before starting of irradiation. This policy was
mandatory because a decrease in the volume of the prostate
gland during the course of irradiation may result in position
changes of the organs at risk and could shift them into
volume of higher irradiation dose.
6. Conclusions
Our results showed that WPRT combined with N-ADT and
L-ADT compared to PORT combined with N-ADT and L-
ADT had an advantage for CSS and bPFS. WPRT was well
tolerated with modest acute and late gastrointestinal and
genitourinary toxicity. It is obvious that N-ADT plus WPRT
could be standard of care for high-risk patients, but question
concerned the gain in OS is still open.
References
[1] F. Bray, R. Sankila, J. Ferlay, and D. M Parkin, “Estimates of
cancer incidence and mortality in Europe in 1995,” European
Journal of Cancer, vol. 38, no. 1, pp. 99–166, 2002.
[ 2 ]R .J .B l a c k ,F .B r a y ,J .F e r l a y ,a n dD .M .P a r k i n ,“ C a n c e r
incidence and mortality in the European union: cancer
registry data and estimates of national incidence for 1990,”
European Journal of Cancer Part A, vol. 33, no. 7, pp. 1075–
1107, 1997.Journal of Biomedicine and Biotechnology 7
[3] R. T. Greenlee, M. B. Hill-Harmon, T. Murray, and M. Thun,
“Cancer statistics, 2001,” CA: A Cancer Journal for Clinicians,
vol. 51, no. 1, pp. 15–36, 2001.
[4] G. D. Grossfeld, J. J. Chang, J. M. Broering, et al., “Impact
of positive surgical margins on prostate cancer recurrence
and the use of secondary cancer treatment: data from the
CaPSURE database,” Journal of Urology, vol. 163, no. 4, pp.
1171–1177, 2000.
[5] A. L. Zietman, “Dose escalation in localized prostate cancer:
make no assumptions,” International Journal of Radiation
Oncology Biology Physics, vol. 54, no. 3, pp. 635–636, 2002.
[6] G. E. Hanks, T. F. Pajak, A. Porter, et al., “Phase III trial of
long-term adjuvant androgen deprivation after neoadjuvant
hormonal cytoreduction and radiotherapy in locally advanced
carcinoma of the prostate: the Radiation Therapy Oncology
Group Protocol 92–02,” Journal of Clinical Oncology, vol. 21,
no. 21, pp. 3972–3978, 2003.
[7] J. Laverdi` ere, J. L. Gomez, L. Cusan, et al., “Beneﬁcial
eﬀect of combination hormonal therapy administered prior
and following external beam radiation therapy in localized
prostate cancer,” International Journal of Radiation Oncology
Biology Physics, vol. 37, no. 2, pp. 247–252, 1997.
[8] M. Roach III, J. Lu, M. V. Pilepich, et al., “Predicting long-
term survival, and the need for hormonal therapy: a meta-
analysis of RTOG prostate cancer trials,” International Journal
of Radiation Oncology Biology Physics, vol. 47, no. 3, pp. 617–
627, 2000.
[9] M. V. Pilepich, K. Winter, C. A. Lawton, et al., “Androgen
suppression adjuvant to deﬁnitive radiotherapy in prostate
carcinoma—long-term results of phase III RTOG 85-31,”
International Journal of Radiation Oncology Biology Physics,
vol. 61, no. 5, pp. 1285–1290, 2005.
[10] M. Roach III, M. DeSilvio, C. Lawton, et al., “Phase III trial
comparing whole-pelvic versus prostate-only radiotherapy
and neoadjuvant versus adjuvant combined androgen sup-
pression: Radiation Therapy Oncology Group 9413,” Journal
of Clinical Oncology, vol. 21, no. 10, pp. 1904–1911, 2003.
[11] M. Roach III, M. DeSilvio, R. Valicenti, et al., “Whole-
pelvis, “mini-pelvis,” or prostate-only external beam radio-
therapy after neoadjuvant and concurrent hormonal therapy
in patients treated in the Radiation Therapy Oncology Group
9413trial,”InternationalJournalofRadiationOncologyBiology
Physics, vol. 66, no. 3, pp. 647–653, 2006.
[12] C. E. Vargas, R. Galalae, J. Demanes, et al., “Lack of beneﬁt of
pelvic radiation in prostate cancer patients with a high risk of
positive pelvic lymph nodes treated with high-dose radiation,”
International Journal of Radiation Oncology Biology Physics,
vol. 63, no. 5, pp. 1474–1482, 2005.
[13] A. Zapatero, F. Garcia-Vicente, I. Modolell, et al., “Impact of
mean rectal dose on late rectal bleeding after conformal radio-
therapy for prostate cancer: dose-volume eﬀect,” International
Journal of Radiation Oncology Biology Physics, vol. 59, no. 5,
pp. 1343–1351, 2004.
[14] S. S. Ploysongsang, B. S. Aron, and W. M. Shehata, “Radiation
therapy in prostate cancer: whole pelvis with prostate boost
or small ﬁeld to prostate?” Urology, vol. 40, no. 1, pp. 18–26,
1992.
[15] C. A. Lawton, M. DeSilvio, M. Roach III, et al., “An update
of the phase III trial comparing whole pelvic to prostate
onlyradiotherapyandneoadjuvanttoadjuvanttotalandrogen




[16] S. A. Seaward, V. Weinberg, P. Lewis, B. Leigh, T. L. Phillips,
and M. Roach III, “Improved freedom from PSA failure
with whole pelvic irradiation for high-risk prostate cancer,”
International Journal of Radiation Oncology Biology Physics,
vol. 42, no. 5, pp. 1055–1062, 1998.
[17] S. A. Seaward, V. Weinberg, P. Lewis, B. Leigh, T. L. Phillips,
andM.RoachIII,“Identiﬁcationofahigh-riskclinicallylocal-
ized prostate cancer subgroup receiving maximum beneﬁt
from whole-pelvic irradiation,” Cancer Journal from Scientiﬁc
American, vol. 4, no. 6, pp. 370–377, 1998.
[18] M.RoachIII,C.Marquez,H.-S.Yuo,etal.,“Predictingtherisk
of lymph node involvement using the pre-treatment prostate
speciﬁc antigen and Gleason Score in men with clinically
localized prostate cancer,” International Journal of Radiation
Oncology Biology Physics, vol. 28, no. 1, pp. 33–37, 1994.
[19] M. Roach III, G. Hanks, H. Thames Jr., et al., “Deﬁning
biochemical failure following radiotherapy with or without
hormonal therapy in men with clinically localized prostate
cancer: recommendations of the RTOG-ASTRO Phoenix
Consensus Conference,” International Journal of Radiation
Oncology Biology Physics, vol. 65, no. 4, pp. 965–974, 2006.
[20] P. Milecki, T. Piotrowski, and M. Dymnicka, “The comparison
of radiotherapy techniques for treatment of the prostate
cancer: the three-ﬁeld vs. the four-ﬁeld,” Neoplasma, vol. 51,
no. 1, pp. 64–69, 2004.
[21] J. D. Cox, J. Stetz, and T. F. Pajak, “Toxicity criteria of
the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer
(EORTC),”InternationalJournalofRadiationOncologyBiology
Physics, vol. 31, no. 5, pp. 1341–1346, 1995.
[22] American Society for Therapeutic Radiology, Oncology Con-
sensus Panel, “Consensus statement: guidelines for PSA fol-
lowing radiation therapy,” International Journal of Radiation
Oncology Biology Physics, vol. 37, no. 5, pp. 1035–1041, 1997.
[23] P. Dirix, K. Haustermans, S. Junius, R. Withers, R. Oyen, and
H. Van Poppel, “The role of whole pelvic radiotherapy in
locally advanced prostate cancer,” Radiotherapy and Oncology,
vol. 79, no. 1, pp. 1–14, 2006.
[24] AmericanUrologyAssociationGuidelinesforProstateCancer,
http://www.auanet.org.
[25] European Urology Association Guidelines for Prostate Cancer,
http://www.uroweb.org.
[26] National Cancer Comprehensive Network .Prostate Cancer,
v.2, 2008, http://www.nccn.org.
[27] M. Bolla, D. Gonzalez, P. Warde, et al., “Improved survival
in patients with locally advanced prostate cancer treated with
radiotherapy and goserelin,” The New England Journal of
Medicine, vol. 337, no. 5, pp. 295–300, 1997.
[28] M. V. Pilepich, K. Winter, C. A. Lawton, et al., “Androgen
suppression adjuvant to deﬁnitive radiotherapy in prostate
carcinoma—long-term results of phase III RTOG 85-31,”
International Journal of Radiation Oncology Biology Physics,
vol. 61, no. 5, pp. 1285–1290, 2005.
[29] P. Milecki, Z. Kwias, and D. J. Martenka, “Radiotherapy
combined with hormonal therapy (RT-HT) in prostate cancer
patients with low, intermediate, and high risk of biochemical
recurrence: perspective and therapeutic gain analysis,” Neo-
plasma, vol. 54, no. 1, pp. 7–15, 2007.
[30] D. Wang and C. Lawton, “Pelvic lymph node irradiation for
prostate cancer: who, why, and when?” Seminars in Radiation
Oncology, vol. 18, no. 1, pp. 35–40, 2008.
[31] M.V.Pilepich,K.Winter,M.J.John,etal.,“PhaseIIIradiation
therapy oncology group (RTOG) trial 86-10 of androgen
deprivation adjuvant to deﬁnitive radiotherapy in locally8 Journal of Biomedicine and Biotechnology
advanced carcinoma of the prostate,” International Journal of
Radiation Oncology Biology Physics, vol. 50, no. 5, pp. 1243–
1252, 2001.
[32] J. Friedman, R. L. Dunn, D. Wood, et al., “Neoadjuvant
docetaxel and capecitabine in patients with high risk prostate
cancer,” Journal of Urology, vol. 179, no. 3, pp. 911–916, 2008.
[33] A. V. D’Amico, J. Manola, M. Loﬀr e d o ,A .A .R e n s h a w ,A .
DellaCroce, and P. W. Kantoﬀ, “6-month androgen suppres-
sion plus radiation therapy vs radiation therapy alone for
patientswithclinicallylocalizedprostatecancer:arandomized
controlled trial,” Journal of the American Medical Association,
vol. 292, no. 7, pp. 821–827, 2004.
[34] J.Crook,C.Ludgate,S.Malone,etal.,“Reportofamulticenter
Canadian phase III randomized trial of 3 months vs. 8
months neoadjuvant androgen deprivation before standard-
dose radiotherapy for clinically localized prostate cancer,”
International Journal of Radiation Oncology Biology Physics,
vol. 60, no. 1, pp. 15–23, 2004.
[35] M. Bolla, L. Collette, L. Blank, et al., “Long-term results with
immediate androgen suppression and external irradiation in
patients with locally advanced prostate cancer (an EORTC
study): a phase III randomised trial,” The Lancet, vol. 360, no.
9327, pp. 103–108, 2002.
[36] J. W. Denham, A. Steigler, D. S. Lamb, et al., “Short-term
androgen deprivation and radiotherapy for locally advanced
prostate cancer: results from the Trans-Tasman Radiation
Oncology Group 96.01 randomised controlled trial,” Lancet
Oncology, vol. 6, no. 11, pp. 841–850, 2005.
[37] M. Roach III, K. Bae, J. Speight, et al., “Short-term neoadju-
vant androgen deprivation therapy and external-beam radio-
therapy for locally advanced prostate cancer: long-term results
of RTOG 8610,” Journal of Clinical Oncology, vol. 26, no. 4, pp.
585–591, 2008.
[38] M. J. Zelefsky, S. A. Leibel, C. M. Burman, et al., “Neoadjuvant
hormonal therapy improves the therapeutic ratio in patients
with bulky prostatic cancer treated with three-dimensional
conformal radiation therapy,” International Journal of Radia-
tionOncologyBiologyPhysics,vol.29,no.4,pp.755–761,1994.